DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study

N Narula,F Peerani,T Hansen,T Bessissow,B Bressler,A Arun,M Schmit,J A Castelli,J K Marshall
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0086
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with several case series reporting effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there remains a paucity of prospective data evaluating its efficacy and rapidity of onset in ASUC. Methods The TRIUMPH study is a phase 4 prospective interventional trial of tofacitinib in ASUC conducted in five hospitals across Canada (Clinicaltrials.gov: NCT04925973). Patients with ASUC (biologic naïve and experienced) refractory to three days of intravenous corticosteroids (Modified Truelove-Witts Severity Index [MTWSI] > 10 despite steroids) were eligible for enrollment. Patients were treated with tofacitinib 10mg bid and assessed daily while in hospital. The primary outcome was day 7 clinical response (MTWSI reduction of > 3 from baseline and < 10). Secondary outcomes included rapidity of clinical and biomarker improvements over the first 7 days, colectomy over the course of one year, and corticosteroid-free clinical remission (total Mayo score < 2), endoscopic improvement (endoscopic Mayo score 0 or 1), and adverse events at 3, 6, and 12 months. Results This is an interim analysis as the study has been fully recruited with six-month follow-up available for all participants. 24 patients with ASUC were recruited and received tofacitinib 10mg bid. The mean total baseline Mayo score was 10.1 (SD 1.4) and all patients had a baseline Mayo endoscopic subscore of 2 (25%, 6/24) or 3 (75%, 18/24). One third of the patients (8/24) had previous anti-TNF failure. Day 7 clinical response was achieved in 58.3% (14/24) patients. The mean number of days to achieve clinical response was 2.4 days (SD 1.3). Marked reduction in C-reactive protein was observed in responders as soon as one day after tofacitinib initiation compared to non-responders (Figure 1). Colectomy occurred in 16.7% (4/24) patients by day 7 and 25% (6/24) by six months. At six months, 45.8% (11/24) patients remained on tofacitinib (including 78.6% (11/14) of day 7 responders), with 33.3% (8/24) having achieved endoscopic improvement and corticosteroid-free clinical remission. A total of six patients reported adverse events, one of which was considered severe (stroke at day 3 after initiation of tofacitinib). Conclusion Tofacitinib may be an effective induction strategy in patients hospitalized with steroid-refractory ASUC. Randomized controlled trials are needed to compare JAK inhibitors with infliximab for steroid refractory ASUC.
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the effectiveness and rapid onset time of using tofacitinib as a treatment method in patients with acute severe ulcerative colitis (ASUC). Specifically, the study focuses on the application effect of tofacitinib in hospitalized ASUC patients who are unresponsive to intravenous corticosteroids. The study evaluates the clinical response speed, short - term and long - term efficacy, and safety of tofacitinib in these patients through a phase 4 prospective intervention trial named TRIUMPH. The research background indicates that although several case series have reported the effectiveness of tofacitinib in ASUC patients, there is a lack of prospective data to systematically evaluate its efficacy and speed of action in this specific population. Therefore, this study aims to fill this knowledge gap and provide more reliable evidence to support tofacitinib as a potential treatment option for ASUC.